项目 1 病毒基因组学：监测、流行病学、宿主反应和病毒免疫原性-猫眼课题宝

项目 1 病毒基因组学：监测、流行病学、宿主反应和病毒免疫原性

批准号：

10163684

负责人：

Pardis Christine Sabeti

金额：

$35.0万

依托单位：

BROAD INSTITUTE, INC.

依托单位国家：

美国

项目类别：

财政年份：

2014

资助国家：

美国

项目状态：

已结题

起止时间：

2014-04-10 至 2024-03-31

来源：

https://reporter.nih.gov/project-details/10163684

关键词：

2019-nCoV Address Award Biological Assay Boston COVID-19 Cessation of life China Chiroptera Cities Clinical Clustered Regularly Interspaced Short Palindromic Repeats Communities Complement Coronavirus Data Devices Diagnostic Discriminant Analysis Discrimination Disease Outbreaks Disease Surveillance Epidemiology Etiology Evaluation Evolution Genome Genomic Centers for Infectious Diseases Genomics Glare Goals Human Hybrids Immune response Individual Influenza Internet Laboratories Libraries Lighting Location Logistic Regressions Lung diseases Measures Metagenomics Methods Monitor Mutation Names National Institute of Allergy and Infectious Disease Oligonucleotides Pathogenicity Pneumonia Population Process Province Public Health Reporting Resources Running Sampling Screening procedure Seafood Sensitivity and Specificity Severe Acute Respiratory Syndrome Signal Transduction Site Specimen Sum Technology Testing Time United States Variant Viral Viral Genome Virus Work base clinical diagnostics communicable disease diagnosis computational pipelines convolutional neural network cost data sharing design diagnostic assay genome sequencing human coronavirus immunogenicity improved insight interest iterative design meetings metagenome mobile computing novel parallelization pathogen point of care prototype respiratory response tool viral genomics whole genome

项目摘要

项目成果

Pardis Christine Sabeti的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

This proposal is intended to develop novel clinical diagnostics for, and increase our understanding of, the diversity, evolution, and spread of the newly emerged SARS-related coronavirus 2 (SARS-CoV-2) and other respiratory disease-causing pathogens in the United States. Coronavirus Disease 2019 (COVID-19) is associated with mild to severe respiratory disease, which can be fatal. The novel viral etiological agent was first identified in December 2019 in Wuhan City, Hubei Province, China following an outbreak of pneumonia in individuals associated with a seafood market, and has since spread globally. Originally named “2019 novel coronavirus”, the virus has since been renamed severe acute respiratory syndrome-related coronavirus (SARS-CoV-2). As of 10 February 2020, this includes 40,554 confirmed cases and 910 deaths within 25 countries1. There have been 12 confirmed cases of COVID-19 in the United States2, one of which was identified in Boston, MA in an individual who recently returned from China3. As public health agencies continue to monitor, track, and attempt to control its spread, it is most crucial that they are equipped with the most effective tools to detect SARS-CoV-2 and distinguish it from other common causes of similar respiratory illness. This proposal addresses the critical gap in clinical diagnostics amidst the quickly moving COVID-19 outbreak by advancing multiplexed and point of care tools for screening a large number of respiratory disease samples in a public health lab setting. It builds upon the genomic disease surveillance aims of the Viral project within our existing Genomic Centers for Infectious Disease (NIAID), but accounts for the increased costs based on the scale of work related to outbreak response. The tools generated by this project specifically address a glaring need at the public health laboratory level and have the potential to accelerate their investigative abilities for undiagnosed respiratory disease.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文